Candiani Massimo, Ottolina Jessica, Schimberni Matteo, Tandoi Iacopo, Bartiromo Ludovica, Ferrari Stefano
Gynecology Department, IRCCS San Raffaele Scientific Institute, Milan, Italy (all authors).
Gynecology Department, IRCCS San Raffaele Scientific Institute, Milan, Italy (all authors)..
J Minim Invasive Gynecol. 2020 May-Jun;27(4):901-908. doi: 10.1016/j.jmig.2019.07.027. Epub 2019 Aug 1.
To assess postoperative recurrence rates in patients with endometriomas managed by either "one-step" CO fiber laser vaporization or cystectomy.
Retrospective study with prospective recording of data.
University hospital.
One hundred twenty-five patients with symptomatic endometriomas.
Patients underwent a standardized laparoscopic stripping technique (group 1) or cyst vaporization with CO fiber laser (group 2). After surgery, patients were incorporated in a prolonged surveillance program with periodic clinical follow-up to check for recurrence of the cyst and/or recurrence of symptoms. Endometrioma recurrence was defined as an ovarian cyst (>10 mm) with a typical aspect arising on the operated ovary identified by transvaginal ultrasound.
The primary endpoint was the comparison of recurrence rates between the 2 groups. The secondary endpoint was the evaluation of endometriosis-related pain recurrence in the 2 groups. Other endpoints selected for analysis included the identification of risk factors for the recurrence of endometrioma and of endometriosis-related symptoms. The mean follow-up was 29 ± 13 months (range, 13-49). Recurrence of ovarian endometriosis was recorded in 6.3% of patients (n = 4) treated with cystectomy and in 4.9% of patients (n = 3) managed with CO fiber laser (p = .74). Recurrence of endometriosis-related pain was observed in 5 patients (7.8%) in group 1 and in 6 patients (9.8%) in group 2 (p = .67). Mean endometrioma diameter > 5 cm at the time of surgery was identified as the only independent poor prognostic indicator for cyst recurrence (p = .008; odds ratio [OR], 2.21; 95% confidence interval [CI], 1.19-3.32). Moreover, the presence of deep endometriosis at surgery (p = .032; OR, 4.60; 95% CI, 1.14-18.57) and discontinuation of hormonal treatment (p = .015; OR, 3.18; 95% CI, 1.25-8.06) were independent poor prognostic indicators for pain recurrence.
This study suggests that one-step CO fiber laser vaporization may be effective for endometrioma treatment because it is associated with recurrence rates comparable with those occurring after cystectomy, with the advantage of being an ovarian tissue-sparing technique.
评估采用“一步法”CO2光纤激光汽化术或囊肿切除术治疗的子宫内膜异位囊肿患者的术后复发率。
回顾性研究,前瞻性记录数据。
大学医院。
125例有症状的子宫内膜异位囊肿患者。
患者接受标准化腹腔镜剥除术(第1组)或CO2光纤激光囊肿汽化术(第2组)。术后,患者纳入长期监测计划,定期进行临床随访,以检查囊肿复发和/或症状复发情况。子宫内膜异位囊肿复发定义为经阴道超声检查发现手术侧卵巢出现典型特征的卵巢囊肿(直径>10mm)。
主要终点是比较两组的复发率。次要终点是评估两组中与子宫内膜异位症相关的疼痛复发情况。选择进行分析的其他终点包括确定子宫内膜异位囊肿复发和与子宫内膜异位症相关症状复发的危险因素。平均随访时间为29±13个月(范围13 - 49个月)。接受囊肿切除术治疗的患者中有6.3%(n = 4)记录有卵巢子宫内膜异位症复发,接受CO2光纤激光治疗的患者中有4.9%(n = 三)复发(p = 0.74)。第1组有5例患者(7.8%)出现与子宫内膜异位症相关的疼痛复发,第2组有6例患者(9.8%)出现复发(p = 0.67)。手术时子宫内膜异位囊肿平均直径>5cm被确定为囊肿复发的唯一独立不良预后指标(p = 0.008;比值比[OR],2.21;95%置信区间[CI],1.19 - 3.32)。此外,手术时存在深部子宫内膜异位症(p = = = 0.032;OR,4.60;95% CI,1.14 - 18.57)和停止激素治疗(p = 0 = 015;OR,3.18;95% CI,1.25 - 8.06)是疼痛复发的独立不良预后指标。
本研究表明,“一步法”CO2光纤激光汽化术可能对子宫内膜异位囊肿治疗有效,因为其复发率与囊肿切除术后相当,且具有保留卵巢组织的优势。